Enzychem Lifesciences Corporation

A183490

KR7183490002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 02/06/2024 BST			5-day change	1st Jan Change
1,939 ^KRW	+0.99%		+4.08%	+6.66%

04-05	Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares.	CI
04-05	Enzychem Lifesciences Corporation authorizes a Buyback Plan.	CI

Enzychem Lifesciences Corporation announced that it has received KRW 50 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Kiwoom Securities Co., Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm

November 15, 2020

On November 16, 2020, Enzychem Lifesciences Corporation (KOSDAQ:A183490) closed the transaction.

Latest news about Enzychem Lifesciences Corporation

Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares.	04-05	CI
Enzychem Lifesciences Corporation authorizes a Buyback Plan.	04-04	CI
Enzychem Lifesciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Enzychem Lifesciences Announces Completion of Clinical Study Report for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis	09/03/22	CI
Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences	02/02/22	CI
Hanmi Pharma to Manufacture COVID-19 Vaccine Developed by India's Zydus Cadila	12/01/22	MT
Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries with Enzychem Lifesciences	04/01/22	CI
Enzychem Lifesciences Corporation to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea	26/11/21	CI
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot	24/11/21	RE
Enzychem Lifesciences Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis	08/11/21	CI
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis	20/10/21	CI
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of Ec-18 in Chemoradiation-Induced Oral Mucositis	13/09/21	CI
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program	20/04/21	CI
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis	06/04/21	CI
Enzychem Lifesciences Corporation announced that it has received KRW 6.5006487 billion in funding	07/03/21	CI
Enzychem Lifesciences Corporation announced that it has received KRW 23.5014976 billion in funding	02/03/21	CI
Enzychem Lifesciences Corporation announced that it expects to receive KRW 6.5006487 billion in funding	25/02/21	CI
Enzychem Lifesciences Corporation announced that it expects to receive KRW 23.5014976 billion in funding	22/02/21	CI
Enzychem Lifesciences Corporation announced that it has received KRW 50 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Kiwoom Securities Co., Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm	15/11/20	CI
Enzychem Lifesciences Corporation announced that it expects to receive KRW 50 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Kiwoom Securities Co., Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm, and other investors	03/11/20	CI
Enzychem Lifesciences Corp. Announces U.S. Food and Drug Administration Acceptance of Phase 2 Study of EC-18	13/08/20	CI
Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome due to COVID-19 Pneumonia	13/07/20	CI
Enzychem Lifesciences Appoints Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug	18/05/20	CI
Enzychem Lifesciences Initiates Phase 2 Study for EC-18 in Preventing Acute Respiratory Distress Syndrome due to Novel Coronavirus Pneumonia	14/05/20	CI
Enzychem Lifesciences Announces Plans to Advance Clinical Trial in South Korea for EC-18 as a Potential Therapeutic for Covid-19 Infection	17/03/20	CI

Chart Enzychem Lifesciences Corporation

Duration

Period

More charts

ENZYCHEM LIFESCIENCES CORPORATION is a Korea-based Company mainly engaged in the development and manufacture of medical raw materials. The Company provides D-cycloserine, a synthetic product utilizing chiral technology to treat tuberculosis; antibiotics, such as terizidone, cefbuperazone, cefazedone and others; magnetic resonance imaging (MRI) contrast agents such as gadoterate and gadopentate; others for antithrombotic drugs, antiinflammatory analgesic drugs, and drugs for gastric ulcer and hyperlipidemia. The Company also provides functional health food and finished drug products.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ENZYCHEM LIFESCIENCES CORPORATION	+6.66%	120M
ELI LILLY AND COMPANY	+42.60%	748B
NOVO NORDISK A/S	+34.01%	598B
JOHNSON & JOHNSON	-5.74%	356B
MERCK & CO., INC.	+17.79%	325B
ABBVIE INC.	+3.37%	283B
ASTRAZENECA PLC	+17.23%	245B
NOVARTIS AG	+9.39%	211B
ROCHE HOLDING AG	-3.84%	209B
PFIZER, INC.	+1.81%	166B

Other Pharmaceuticals